Elacytarabine lipid vector technology overcoming drug resistance in acute myeloid leukemia

Expert Opinion on Investigational Drugs

Volumn 20, Issue 12, 2011, Pages 1707-1715

  Burke, Aine Carol ^a   Giles, Frank James ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Acute myeloid leukemia; Ara C; CP 4055; Cytarabine; Drug development; Elacytarabine

Indexed keywords

ELACYTARABINE; IDARUBICIN; LIPID; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER SURVIVAL; CELL CYCLE; COLORECTAL CANCER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; NEUTROPENIA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR XENOGRAFT; TYPHLITIS;

ANTINEOPLASTIC AGENTS; CYTARABINE; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY;

EID: 81555228401     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.625009     Document Type: Article

References (49)

1. Giles F, O'Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer, 2005;104(3):547-54 (Pubitemid 41022812)
2. Liliemark JO, Plunkett, W, Dixon, DO. Relationship of 1-beta-Darabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5¢-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine. Cancer Res, 1985. 45(11 Pt 2):5952-7 (Pubitemid 16218617)
3. Abdel-Aziz W, Jiang HY, Hickey RJ, Malkas, LH. Ara-C affects formation of cancer cell DNA synthesome replication intermediates. Cancer Chemother Pharmacol 2000;45(4):312-19 (Pubitemid 30151525)
4. Perrino FW, Mekosh HL. Incorporation of cytosine arabinoside monophosphate into DNA at internucleotide linkages by human DNA polymerase alpha. J Biol Chem 1992;267(32):23043-51
5. Estey E, Plunkett W, Dixon D, et al. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leukemia 1987;1(8):580-3 (Pubitemid 18005688)
6. Kufe D, Spriggs, D, Egan, EM, et al. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 1984;64(1):54-8 (Pubitemid 14085726)
7. Wiley JS, Jones SP, Sawyer WH. Cytosine arabinoside transport by human leukaemic cells. Eur J Cancer Clin Oncol 1983;19(8):1067-74 (Pubitemid 13045312)
8. Rampazzo C, Gazziola C, Ferraro L, et al. Human high-Km 5¢-nucleotidase effects of overexpression of the cloned cDNA in cultured human cells. Eur J Biochem 1999;261(3):689-97 (Pubitemid 29226066)
9. Laliberte J, Momparler RL. Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res 1994;54(20):5401-7 (Pubitemid 24336032)
10. Coleman CN, Stoller RG, Drake JC, et al. Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood 1975;46(5):791-803
11. Galmarini CM, Thomas X, Calvo F, et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002;117(4):860-8 (Pubitemid 34639247)
12. Rubas W, Supersaxo A, Weder HG, et al. Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 1986;37(1):149-54 (Pubitemid 16186632)
13. Peters GJ, Voorn DA, Kuiper CM, et al. Cell specific cytotoxicity and structure-activity relationship of lipophilic 1-B-D-arabinofuranosylcytosine (ara-C) derivatives. Nucleosides Nucleotides 1999;18(4-5):877-8 (Pubitemid 29320619)
14. Kuiper CM, Van der Wilt CL, Noordhuis P, et al. Lipophilic 1-Beta-D-arabinofuranosyl cytosine (ara-C) derivatives: cell specific cytotoxicity and structure-activity relationship (SAR). Proc Am Assoc Cancer Res 1998;39:306-10
15. Bergman AM, Kuiper CM, Voorn DA, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 2004;67(3):503-11 (Pubitemid 38232890)
16. Clavis Pharma Ltd Web Site. Available from: http://www.clavispharma.com/ Technology
17. Burke A, Swords R, Kelly K, et al. Elacytarabine. Drugs Future 2009;34(12):941-9
18. Boleti H, Coe IR, Baldwin SA, et al. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology 1997;36(9):1167-79 (Pubitemid 27465605)
19. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D-arabinofuranosylcytosine. Cancer Res 1984;44(11):5029-37 (Pubitemid 15204459)
20. Gati WP, Paterson AR, Larratt LM, et al. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 1997;90(1):346-53 (Pubitemid 27276580)
21. Cai J, Damaraju VL, Groulx N, et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 2008;68(7):2349-57 (Pubitemid 351521809)
22. Wiley JS, Taupin J, Jamieson GP, et al. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 1985;75(2):632-42 (Pubitemid 15142074)
23. Adema A, Smid K, Losekoot N, et al. Fatty acid derivatives of cytarabine and gemcitabine, CP-4055 and CP-4126, show a prolonged cellular retention compared to the parent drug. AACR Meeting Abstracts 2008;2008(1 Annual Meeting): 5740-5741
24. Breistol K, Balzarini J, Sandvold ML, et al. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models. Cancer Res 1999;59(12):2944-9 (Pubitemid 29283136)
25. Galmarini CM, Myhren F, Sandvold ML. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol 2009;144(2):273-5
26. Jin G, Matsushita H, Asai S, et al. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun 2009;390(3):1001-6
27. Clavis Pharma Press Release 2011. Available from: http://www. clavispharma.com/News+%26+Events/2011+Press+releases/844.cms
28. Bergman AM, Kuiper CM, Myhren F, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines. Nucleosides Nucleotides Nucleic Acids 2004;23(8-9):1523-6 (Pubitemid 39625956)
29. Milano G, Chamorey AL, Thyss A. Clinical pharmacology of nucleoside analogues. Bull Cancer 2002;89:S71-5
30. Adema AD, Laan AC, Myhren F, et al. Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel. Int J Oncol 2010;36(1):285-94
31. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003;22(56):9063-74 (Pubitemid 38121707)
32. Aamdal S, Dueland S, Lind MJ, et al. Favorable phase I clinical results and pharmacokinetic (PK) data with the novel lipid vector technology-cytotoxic agent, CP-4055. AACR Meeting Abstracts 2005;2005(1):936
33. Aamdal S, Dueland S, Lind MJ, et al. Phase I trial of a nucleoside analog CP-4055 given daily for 5 days every 3 weeks in patients (pts) with advanced solid tumors-preliminary results. ASCO Meeting Abstracts 2004;22(14 Suppl):2049
34. Delaunoit T, Raymond E, Awada A, et al. A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors. ASCO Meeting Abstracts 2006;24(18 Suppl):2067
35. Dueland S, Aamdal S, Lundgren L, et al. A multicentre, dose finding, phase II study of CP-4055 in combination with sorafenib in patients with metastatic malignant melanoma. ASCO Meeting Abstracts 2008;26(15 Suppl):20029
36. Raymond E, Dueland SM, Lind J, et al. Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules. AACR Meeting Abstracts 2005;2005(1):936
37. Dueland S, Aamdal S, Lind MJ, et al. Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study. Acta Oncol 2009;48(1):137-45
38. Raymond E, Awada A, Culine S, et al. Phase I trial of CP-4055, a novel cytotoxic agent, given according to three intermittent weekly or biweekly schedules in patients with advanced or metastatic solid tumors: preliminary results. AACR Meeting Abstracts 2005;2005(1):110-c-111
39. Dueland S, Aamdal S, Nyakas M, et al. A multicentre, dose-finding, phase II Study of CP-4055 in combination with sorafenib in patients with metastatic malignant melanoma. In European Society for Medical Oncology; Stockholm, Sweden; 2008
40. Giles F, O'Brien S, Vey N, et al. A phase I study with CP-4055 in patients with haematologic malignancies [abstract #0036]. EHA 13th Congress Copenhagen; Denmark; 2008
41. O'Brien S, Rizzieri DA, Vey N, et al. A phase I/II study with CP-4055 in patients with haematologic malignancies. Blood 2008;112(11):949
42. O'Brien S, Rizzieri D, Padmanabhan S, et al. A phase I study with CP-4055 and idarubicin in patients with refractory/relapsed AML [abstract #0310]. EHA 14th Congress; Berlin, Germany; 2009
43. O'Brien S, Rizzieri D, Vey N, et al. A phase II study with CP-4055 as second salvage therapy in patients with AML [abstract #1394]. EHA 14th Congress; Berlin, Germany; 2009
44. O'Brien S, Rizzieri D, Vey N, et al. A phase II multicentre study with elacytarabine as second salvage therapy in patients with AML. Blood 2009;114(22):1042
45. Giles FJ, O'Brien S, Rizzieri DA, et al. A phase II study with CP-4055 in patients with second salvage AML. J Clin Oncol 2009;27(15 Suppl):abstract 7047
46. Rizzieri D, Krug U, Schlenk RF, et al. A phase II study of elacytarabine plus idarubicin as second course remission-induction therapy in patients with acute myeloid leukemia. J Clin Oncol 2011;29(Suppl):abstract TPS207
47. Rizzieri D, Vey N, Gobbi M, et al. A randomized phase III study of elacytarabine versus limited investigator's choice in patients with refractory acute myeloid leukemia (AML). J Clin Oncol 2011;29(Suppl):abstract TPS206
48. Adams DJ, Sandvold ML, Myhren F, et al. Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 2008;49(4):786-97 (Pubitemid 351517226)
49. Bruheim S, Mlandsmo G, Sandvold ML, et al. Antitumor activity of CP-4055 is enhanced in combination with bevacizumab, cetuximab, and trastuzumab in human NSCLC xenografts. AACR Meeting Abstracts 2007; 2007(3-Molecular-Targets- Meeting): B287